Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic option in cardiorenal diseases, mitigating the limitations of steroidal MRAs. Finerenone, a third-generation nonsteroidal MRA, has demonstrated beneficial effects in heart failure (HF) and chronic kidney disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Monarch, Awad, Alaa S., Abdel-Rahman, Emaad M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573495/
https://www.ncbi.nlm.nih.gov/pubmed/37834929
http://dx.doi.org/10.3390/jcm12196285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573495/
https://www.ncbi.nlm.nih.gov/pubmed/37834929
http://dx.doi.org/10.3390/jcm12196285

Ejemplares similares